Mikroliz Therapeutic Bacteriophage Bank (MTBB) is established in Turkey which currently has over 3200 phages against mainly ESKAPE.
Mikroliz, is a preclinical biotechnology company to treat multidrug-resistant bacterial infections. Mikroliz Therapeutic Bacteriophage Bank (MTBB) has established Turkey’s bacteriophage bank against especially ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) pathogens and other life-threatening, especially hospital infections. These phages will be used in personalized clinical bacteriophage therapy in the future and will be a hope especially for terminally ill patients for whom antibiotic treatment is insufficient.
Labs
United Kingdom
Discovery Park, Ramsgate Rd, Sandwich CT13 9FF, U.K
Turkiye
Bahçelievler mah. 323/1 Cad. A. Blok Gazi Üniversitesi Teknokent Binası No/50A 24, 06830 Gölbaşı/Ankara / TURKİYE
Timeline
2010 – Our founder, Dr. Medine Çotak, graduated from Middle East Technical University, Ankara, Turkey.
2014 – Earned a Master’s degree from Rheinische Friedrich-Wilhelms-Universität Bonn, Germany.
2015 – Mikroliz was founded.
2016 – Completed a Master’s degree at Hacettepe University, Turkey.
2019 – Earned a Master’s degree from Middle East Technical University, Turkey.
2019 – Awarded a Doctorate (Ph.D.).
2020 – Secured our first patent.
2020 – Began working as an academic at Iğdır University, Turkey.
2025 – Expanded our laboratories to the UK.